Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TETRALITE Influenza Vaccine in Healthy Adults
NCT05581407Phase 1Completed
- Sponsor
- LiteVax BV
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TETRALITE in influenza (3 arms), sponsored by LiteVax BV. Primary endpoint: Safety and tolerability of a single, intramuscular injection with TETRALITE at 6 months. Started Oct 2022; status: completed.
02
Drugs
TETRALITE
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05581407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581407.